Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models
Roche CEO Severin Schwan says the process of paying for hugely expensive gene therapies that can cure diseases needs revamping.
Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range
PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Cassiopea Hails Breezula's 'Good Hair Day' And Plans FDA Talks On Phase III
Italy-based Cassiopea says “very positive results” from Breezula's 12-month Phase II alopecia trial support progressing it to Phase III, particularly given the clean safety profile.
Gelesis's Obesity Product FDA Acceptance Gives Boost To PureTech's Portfolio
PureTech's affiliate Gelesis has received FDA clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Product Sales, Pipeline & Biosimilar Timelines Key Themes For Roche 1Q
Investors during Roche’s first-quarter update Wednesday will be looking for clues on looming biosimilar competition and timelines for the emergence of promising pipeline assets.
Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.